Anti-Mouse CD248 Antibody (G78)

Catalog No.

FMJ61010

Species reactivity

Human, Mouse

Host species

Human

Isotype

IgG1, lambda

Clonality

Monoclonal

Conjugation

Unconjugated

Target

Endosialin, TEM1, CD164L1, Tumor endothelial marker 1, CD248

Concentration

1.75 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q91V98

Applications

ELISA, FCM

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

G78

Corrigendum to "CXCL12 derived from CD248-expressing cancer-associated fibroblasts mediates M2-polarized macrophages to promote nonsmall cell lung cancer progression" [Biochim. Biophys. Acta Mol. Basis Dis., 1868 (2022) 166521-166521/10.1016/j.bbadis.2022.166521]., PMID:40287323

Dynamic molecular atlas of cardiac fibrosis at single-cell resolution shows CD248 in cardiac fibroblasts orchestrates interactions with immune cells., PMID:40148545

CD248-targeted BBIR-T cell therapy against late-activated fibroblasts in cardiac repair after myocardial infarction., PMID:40148319

Endosialin-positive CAFs promote hepatocellular carcinoma progression by suppressing CD8+ T cell infiltration., PMID:39260826

CD248-expressing cancer-associated fibroblasts induce non-small cell lung cancer metastasis via Hippo pathway-mediated extracellular matrix stiffness., PMID:39164826

CD248 interacts with ECM to promote hypertrophic scar formation and development., PMID:38944165

CD248-expressing cancer-associated fibroblasts induce epithelial-mesenchymal transition of non-small cell lung cancer via inducing M2-polarized macrophages., PMID:38906929

IL-8 from CD248-expressing cancer-associated fibroblasts generates cisplatin resistance in non-small cell lung cancer., PMID:38396325

TEM1/endosialin/CD248 promotes pathologic scarring and TGF-β activity through its receptor stability in dermal fibroblasts., PMID:38254097

Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches., PMID:38164138

[Expression of endosialin in human hypertrophic scars and its regulation on fibroblast phenotype]., PMID:38129304

[IgG78-DM1 inhibits pulmonary fibrosis by targeting and killing CD248-positive myofibroblasts in mice]., PMID:37732571

Endosialin-positive tumor-derived pericytes promote tumor progression through impeding the infiltration of CD8+ T cells in clear cell renal cell carcinoma., PMID:36646951

Soluble tumor endothelial marker 1 in heart failure with reduced ejection fraction: A pilot study., PMID:36588577

CXCL12 derived from CD248-expressing cancer-associated fibroblasts mediates M2-polarized macrophages to promote nonsmall cell lung cancer progression., PMID:35985448

Antibody-drug conjugates targeting CD248 inhibits liver fibrosis through specific killing on myofibroblasts., PMID:35317721

TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodulation and eradication of ovarian cancer., PMID:35087718

Endosialin/CD248 may be a potential therapeutic target to prevent the invasion and metastasis in osteosarcoma., PMID:34976154

Antibody-drug conjugates targeting CD248+ myofibroblasts effectively alleviate renal fibrosis in mice., PMID:34972243

Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1., PMID:34467246

Endosialin (CD248) Expression in Fibromas and Soft-tissue Fibrosarcomas in Dogs., PMID:33910824

CD248 enhances tissue factor procoagulant function, promoting arterial and venous thrombosis in mouse models., PMID:33830628

Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies., PMID:33807678

Biological evaluation of new TEM1 targeting recombinant antibodies for radioimmunotherapy: In vitro, in vivo and in silico studies., PMID:33271301

Oxidative Stress Product, 4-Hydroxy-2-Nonenal, Induces the Release of Tissue Factor-Positive Microvesicles From Perivascular Cells Into Circulation., PMID:33028097

CD248 as a novel therapeutic target in pulmonary arterial hypertension., PMID:32997414

Interaction with CD68 and Regulation of GAS6 Expression by Endosialin in Fibroblasts Drives Recruitment and Polarization of Macrophages in Hepatocellular Carcinoma., PMID:32591411

Preclinical Evaluation and Dosimetry of [111In]CHX-DTPA-scFv78-Fc Targeting Endosialin/Tumor Endothelial Marker 1 (TEM1)., PMID:31993928

Linking myofibroblast generation and microvascular alteration: The role of CD248 from pathogenesis to therapeutic target (Review)., PMID:31257535

A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas., PMID:31034598

CD248: A therapeutic target in cancer and fibrotic diseases., PMID:30847027

A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors., PMID:30623276

Tumour endothelial marker 1/endosialin-mediated targeting of human sarcoma., PMID:29304474

Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213)., PMID:29292843

A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma., PMID:29127533

Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma., PMID:28947977

Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy., PMID:27933426

Novel antibody probes for the characterization of endosialin/TEM-1., PMID:27494870

Endosialin expression in soft tissue sarcoma as a potential marker of undifferentiated mesenchymal cells., PMID:27434038

Endosialin and Associated Protein Expression in Soft Tissue Sarcomas: A Potential Target for Anti-Endosialin Therapeutic Strategies., PMID:27057137

Development of 89Zr-Ontuxizumab for in vivo TEM-1/endosialin PET applications., PMID:26909615

Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature., PMID:26327620

Targeting tumor vasculature: expanding the potential of DNA cancer vaccines., PMID:26267042

Anti-Endosialin Antibody-Drug Conjugate: Potential in Sarcoma and Other Malignancies., PMID:26184481

Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications., PMID:26085332

A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors., PMID:25398449

Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer., PMID:25051365

Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer., PMID:24790428

Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model., PMID:24553243

Characterisation of fibroblast-like synoviocytes from a murine model of joint inflammation., PMID:23363614

Document Download

Anti-Mouse CD248 Antibody (G78).pdf